Study on Using Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Spread to the Liver

Sponsor: Spectrum Health Hospitals

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT03856658

Provider View

This clinical trial is testing a new way to deliver chemotherapy directly to the liver to treat pancreatic cancer that has spread there. Patients will receive standard chemotherapy along with an additional treatment through a special pump placed in the liver's artery.

Patient Parameters

Program Overview

The aim of this study is to see if delivering a chemotherapy drug called Floxuridine (FUDR) directly to the liver through a pump can improve survival rates for patients with pancreatic cancer that has spread to the liver. Participants will receive this treatment along with their regular chemotherapy for six cycles and will be monitored for two years.

Description

This study is exploring a new treatment method for pancreatic cancer that has spread to the liver. It involves using a pump to deliver a chemotherapy drug called Floxuridine (FUDR) directly into the liver's artery. This is done in addition to the usual chemotherapy treatment. The hope is that this approach will help patients live longer. Participants will undergo six cycles of this treatment and will be followed for two years to see how well it works.

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with pancreatic cancer that has spread to the liver, confirmed by a biopsy.
  • Elevated levels of a specific cancer marker (CA19-9) at diagnosis.
  • Aged between 18 and 75 years.
  • Have a good overall health status, with a performance score of 70 or higher.
  • Able to undergo general anesthesia and the procedure to place the pump.
  • Recent imaging scans show that the liver artery is accessible for the pump placement.
  • Have received at least two months of regular chemotherapy with stable results.

Exclusion Criteria

  • The primary pancreatic tumor has been surgically removed.
  • Have a high score on a liver disease assessment (MELD score over 20).
  • More than 60% of the liver is affected by cancer.
  • Cancer has spread to the lining of the abdomen.
  • Current alcohol abuse.
  • Pregnant or breastfeeding women.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.